Related Experiment Videos
Foscarnet for suppression of human immunodeficiency virus replication
C V Fletcher1, A C Collier, F S Rhame
1Department of Pharmacy Practice, University of Minnesota, Minneapolis.
Insights
Foscarnet therapy showed a positive effect in individuals with human immunodeficiency virus (HIV), increasing CD4+ lymphocytes and decreasing HIV antigen levels. This suggests foscarnet
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human immunodeficiency virus (HIV) infection remains a significant global health challenge.
- Antiretroviral therapies are crucial for managing HIV and improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of foscarnet in treating human immunodeficiency virus (HIV).
- To assess the impact of foscarnet on CD4+ lymphocyte counts and HIV antigen levels.
Main Methods:
- Nine individuals with HIV were enrolled in the study.
- Six participants completed 28 days of foscarnet induction therapy.
- Pharmacodynamic modeling was used to relate foscarnet exposure to viral suppression.
Main Results:
- A mean increase of 64 cells/mm³ in CD4+ lymphocytes was observed.
- A statistically significant mean decline of 108 pg/ml in HIV antigen concentration was noted (P = 0.03).
- Foscarnet exposure was correlated with viral suppression via a maximum-effect model.
Conclusions:
- Foscarnet demonstrated a beneficial effect in HIV-infected individuals.
- The drug increased CD4+ counts and reduced viral load, indicating potential as an antiretroviral agent.
- Systemic foscarnet exposure is a key factor in achieving HIV suppression.
Abstract:
The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.